Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Axogen, Inc. (AXGN)

Axogen posts prostate nerve reconstruction investor presentation, no financial results

Neutral Impact 2 of 5 other

Axogen furnished a corporate investor presentation dated November 9, 2026, on its prostate nerve reconstruction opportunity, which it posted to its website and may use in talks with analysts and investors. The filing contains no earnings, guidance, or deal terms, so it gives shareholders a view of management's market case rather than new financial results.

Key points

  • The presentation, titled Prostate Nerve Reconstruction Investor Event, is furnished as Exhibit 99.1 and dated November 9, 2026.
  • The company estimates a total addressable market of $754 million, based on about 110,000 cases per year at a weighted average selling price of about $7,000 per procedure.
  • Clinical data cited include more than 220 patients reconstructed with Avance at six months, with about 80% reporting better than expected erectile function.

The filing

CompanyAxogen, Inc. (AXGN)
Form8-K, current report
Filed with the SECNov 9, 2026, 8:52 AM ET
Accession number0000805928-26-000110

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 9:18 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.